Gary Lyman, MD, MPH, an oncologist and hematologist, compares the uptake of filgrastim biosimlars with pegfilgrastim biosimilars. Gary Lyman, MD, MPH, is an oncologist, hematologist, and public health ...
The US Food and Drug Administration (FDA) has expanded the indication for tbo-filgrastim (Granix, Teva), now allowing it to be self-administered by patients and their caregivers. Tbo-filgrastim, a ...
PURPOSE: This multicenter, randomized, double-blind, active-control study was designed to determine whether a single subcutaneous injection of pegfilgrastim (SD/01, sustained-duration filgrastim; 100 ...
On January 7, 2015, Sandoz, the generics wing of Novartis, announced that the FDA’s Oncologic Drugs Advisory Committee (ODAC) has recommended its biosimilar filgrastim (EP2006) for approval in the ...
The effects of sargramostim and filgrastim on hematopoietic cells are described. Filgrastim is a lineage-specific colonystimulating factor (CSF), mainly affecting neutrophils. In addition to enhancing ...
FRANKFURT (Reuters) - Germany's Stada will sell a version of U.S. drugmaker Amgen's blockbuster cancer treatment filgrastim in Europe, keeping faith with the difficult market for copies of medicines ...
On Friday, the Food and Drug Administration approved a biosimilar version of Amgen's Neupogen® (filgrastim) product for sale in the U.S. This is the first biosimilar to be approved under the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback